Oflon-OZ Tablet contains a combination of Ofloxacin 200 mg and Ornidazole 500 mg, formulated for the treatment of mixed bacterial and protozoal infections. Ofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial DNA replication, transcription, repair, and recombination. Ornidazole is a nitroimidazole derivative effective against anaerobic bacteria and protozoa by causing DNA strand breakage and inhibition of nucleic acid synthesis. This synergistic combination is indicated for infections caused by susceptible organisms, including gastrointestinal infections, genitourinary tract infections, respiratory tract infections, skin and soft tissue infections, and mixed anaerobic infections. Oflon-OZ is particularly useful in treating conditions where both aerobic and anaerobic pathogens are suspected. The medication should be used under medical supervision, with dosage adjusted according to the severity of infection and patient-specific factors such as renal function. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and hypersensitivity reactions. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and it is contraindicated during pregnancy and lactation. Proper adherence to prescribed dosage and duration is essential to prevent resistance development and ensure therapeutic efficacy.